Core D3: Synthetic Antigen Binder Generation & Crystallography
核心 D3:合成抗原结合剂生成
基本信息
- 批准号:7922836
- 负责人:
- 金额:$ 50.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-04-01 至 2015-03-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAntibodiesArtsBacteriaBindingCell surfaceCommunitiesComplexCrystallizationCrystallographyDetergentsEngineeringEnvironmentFab ImmunoglobulinsFigs - dietaryFruitFunctional RNAFutureGenerationsGoalsLibrariesLocationMembrane ProteinsMethodologyMethodsModificationMolecular ChaperonesMolecular ConformationMonoclonal AntibodiesOutcomePerformancePhage DisplayPopulationPreparationPropertyProtein ConformationProtein DynamicsProtein EngineeringProtein Structure InitiativeProteinsReagentRecombinantsResearchResearch InfrastructureResourcesSamplingServicesShapesSideSiteSorting - Cell MovementSpecificityStructureSynthetic AntigensSystemTechnologyUnited States National Institutes of HealthWaterWorkXenopus oocytebasecombinatorialdesignflexibilityimprovedmembernovelnovel strategiesoverexpressionprotein complexprotein functionprotein purificationstructural biologytool
项目摘要
The overarching goal of the Synthetic Antigen Binder "Sab Core" is to provide a broad range of powerful approaches and novel reagents to support the consortium's research objectives. The Sab Core is uniquely capable, based on the expertise and resources that have been developed under the auspices of the NIH Protein Structure Initiative (PSI), to generate in a high-throughput way synthetic antigen binders to an extensive range of targets including soluble proteins, protein complexes, membrane proteins and functional
RNA. Thus, the infrastructure in place with extensive capability to efficiently generate high-quality affinity reagents will dramatically accelerate membrane protein research performed within the MPSD Consortium, as well as in the entire membrane protein research community.
Our previous efforts had focused on generating Sabs for use as "crystallization chaperones" (1). This endeavor has led to the crystallization and structure determination of several high-hanging fruit systems.
Importantly, the Sab technology has a number of additional attributes that our team plans to exploit to investigate structure-dynamics-function relationships of membrane proteins in unique ways. Membrane proteins are dynamic machines that need to change their shape to perform their function. Therefore, it is critically important to functionally and structurally characterize major conformational states and determine how
their populations are modulated during the course of action.
Our Sabs are often exquisitely conformation-specific, making them
powerful probes for studying protein conformation dynamics. They can be used to
"lock" a protein in a specific conformational state, which allows for unequivocal
annotation of functional states (Fig. D3.1). Sabs can stabilize a specific
conformational state to facilitate structural determination. They can also be
engineered for use as affinity reagents to aid membrane protein purification as well
as to stabilize membrane protein targets for storage. The importance of the last
attribute cannot be overstated. Membrane proteins are inherently fragile. Since the
proposed projects in the MPSD Consortium often involve shipment of samples
between different locations, it is essential that they be delivered and stored in their
native states. Further, Sabs can be used to attach spectroscopic probes to a
specific location within a target with minimal modification to the target.
The Sab Core produces three distinct classes of Sabs, in the forms of the antigen-binding fragment (Fab) of antibodies and other designer proteins that collectively fulfill diverse needs in membrane protein research. These Sabs are generated from high-performance phage-display libraries that are designed based
on revolutionary concepts in protein engineering, and Sabs are produced in bacteria. It is our contention that, in the near future. Sabs will replace the traditional monoclonal antibody technology that is slow and expensive.
The goals of the Sab Core are (i) to provide high-quality synthetic affinity reagents for membrane protein targets using state-of-the-art technologies, (ii) to accelerate structure determination by Sab-based chaperone-assisted crystallography and (iii) to develop novel applications of Sabs that will enable Core users to significantly elevate the level of mechanistic understanding of membrane protein functions. Sabs generated
in this Core and ultimately the technology to produce Sabs will be made available to the broader scientific community.
合成抗原结合剂“Sab Core”的总体目标是提供广泛的强大方法和新型试剂,以支持该联盟的研究目标。基于在NIH蛋白质结构倡议(PSI)的赞助下开发的专业知识和资源,Sab Core具有独特的能力,以高通量的方式产生针对广泛范围的靶标的合成抗原结合剂,所述靶标包括可溶性蛋白质、蛋白质复合物、膜蛋白和功能性蛋白质。
核糖核酸因此,具有有效产生高质量亲和试剂的广泛能力的基础设施将大大加速MPSD联盟以及整个膜蛋白研究社区内进行的膜蛋白研究。
我们之前的努力集中在产生用作“结晶伴侣”的Sabs(1)。这一奋进导致了几个高挂水果系统的结晶和结构测定。
重要的是,Sab技术具有许多额外的属性,我们的团队计划利用这些属性以独特的方式研究膜蛋白的结构-动力学-功能关系。膜蛋白是动态机器,需要改变它们的形状来执行它们的功能。因此,在功能和结构上表征主要构象状态并确定如何
它们的种群在行动过程中受到调节。
我们的sab通常是精致的构象特异性,使他们
用于研究蛋白质构象动力学的强有力的探针。它们可用于
“锁定”蛋白质在特定的构象状态,这允许明确的
功能状态注释(图D3.1)。Sabs可以稳定特定的
构象状态,以促进结构确定。它们也可以
也被设计用作亲和试剂以帮助膜蛋白纯化
以稳定膜蛋白靶用于储存。最后的重要性
属性不能被夸大。膜蛋白质本身就很脆弱。以来
MPSD联盟中的拟议项目通常涉及样品的运输
在不同的地点之间,必须将它们交付和储存在
原住民国家此外,可以使用Sabs将光谱探针连接到微阵列。
目标内的特定位置,对目标进行最小的修改。
Sab Core产生三种不同类型的Sabs,以抗体的抗原结合片段(Fab)和其他设计蛋白的形式,共同满足膜蛋白研究的不同需求。这些Sabs是从高性能噬菌体展示库中产生的,
蛋白质工程的革命性概念,而Sabs是在细菌中产生的。我们的论点是,在不久的将来。Sabs将取代传统的单克隆抗体技术,这是缓慢和昂贵的。
Sab Core的目标是(i)使用最先进的技术为膜蛋白靶点提供高质量的合成亲和试剂,(ii)通过基于Sab-based分子伴侣辅助结晶学加速结构测定,以及(iii)开发Sabs的新应用,使Core用户能够显着提高膜蛋白功能的机制理解水平。生成的Sabs
在这个核心中,最终生产太阳能电池的技术将提供给更广泛的科学界。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SHOHEI KOIDE其他文献
SHOHEI KOIDE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SHOHEI KOIDE', 18)}}的其他基金
Novel biologics platform for targeting tumors driven by intracellular oncoproteins
用于靶向细胞内癌蛋白驱动的肿瘤的新型生物制剂平台
- 批准号:
10356663 - 财政年份:2021
- 资助金额:
$ 50.97万 - 项目类别:
Transport Mechanisms and Inhibition of Efflux Pumps in Pathogenic Organisms
病原生物外排泵的转运机制和抑制
- 批准号:
10344321 - 财政年份:2021
- 资助金额:
$ 50.97万 - 项目类别:
Novel biologics platform for targeting tumors driven by intracellular oncoproteins
用于靶向细胞内癌蛋白驱动的肿瘤的新型生物制剂平台
- 批准号:
10533364 - 财政年份:2021
- 资助金额:
$ 50.97万 - 项目类别:
Transport Mechanisms and Inhibition of Efflux Pumps in Pathogenic Organisms
病原生物外排泵的转运机制和抑制
- 批准号:
10531273 - 财政年份:2021
- 资助金额:
$ 50.97万 - 项目类别:
Accurate prediction of neutralization capacity from deep mining of SARS-CoV-2 serology
深度挖掘SARS-CoV-2血清学,准确预测中和能力
- 批准号:
10195613 - 财政年份:2020
- 资助金额:
$ 50.97万 - 项目类别:
Probing RAS-mediated signaling mechanisms with monobody inhibitors
使用单体抑制剂探索 RAS 介导的信号传导机制
- 批准号:
9977135 - 财政年份:2018
- 资助金额:
$ 50.97万 - 项目类别:
Probing RAS-mediated signaling mechanisms with monobody inhibitors
使用单体抑制剂探索 RAS 介导的信号传导机制
- 批准号:
10220892 - 财政年份:2018
- 资助金额:
$ 50.97万 - 项目类别:
Probing RAS-mediated signaling mechanisms with monobody inhibitors
使用单体抑制剂探索 RAS 介导的信号传导机制
- 批准号:
9751810 - 财政年份:2018
- 资助金额:
$ 50.97万 - 项目类别:
Probing RAS-mediated signaling mechanisms with monobody inhibitors
使用单体抑制剂探索 RAS 介导的信号传导机制
- 批准号:
9384266 - 财政年份:2017
- 资助金额:
$ 50.97万 - 项目类别:
Probing RAS-mediated Signaling with Monobody Inhibitors
使用单体抑制剂探测 RAS 介导的信号转导
- 批准号:
10530818 - 财政年份:2017
- 资助金额:
$ 50.97万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 50.97万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 50.97万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 50.97万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 50.97万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 50.97万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 50.97万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 50.97万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 50.97万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 50.97万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 50.97万 - 项目类别:














{{item.name}}会员




